TAILIEUCHUNG - Identifcation of immune subtypes of Phneg B-ALL with ferroptosis related genes and the potential implementation of Sorafenib

The clinical outcome of Philadelphia chromosome-negative B cell acute lymphoblastic leukemia (Phneg B-ALL) varies considerably from one person to another after clinical treatment due to lack of targeted therapies and leukemia’s heterogeneity. | Hong et al. BMC Cancer 2021 21 1331 https s12885-021-09076-w RESEARCH ARTICLE Open Access Identification of immune subtypes of Ph- neg B-ALL with ferroptosis related genes and the potential implementation of Sorafenib Yang Hong1 2 Ling Zhang1 2 Xiaopeng Tian1 2 Xin Xiang1 2 Yan Yu1 2 Zhao Zeng1 2 Yaqing Cao1 2 Suning Chen1 2 and Aining Sun1 2 Abstract Background The clinical outcome of Philadelphia chromosome-negative B cell acute lymphoblastic leukemia Ph- neg B-ALL varies considerably from one person to another after clinical treatment due to lack of targeted therapies and leukemia s heterogeneity. Ferroptosis is a recently discovered programmed cell death strongly correlated with cancers. Nevertheless few related studies have reported its significance in acute lymphoblastic leukemia. Methods Herein we collected clinical data of 80 Ph-neg B-ALL patients diagnosed in our center and performed RNA-seq with their initial bone marrow fluid samples. Throughout unsupervised machine learning K-means clustering with 24 ferroptosis related genes FRGs the clustered patients were parted into three variant risk groups and were performed with bioinformatics analysis. Results As a result we discovered significant heterogeneity of both immune microenvironment and genomic vari- ance. Furthermore the immune check point inhibitors response and potential implementation of Sorafenib in Ph-neg B-ALL was also analyzed in our cohort. Lastly one prognostic model based on 8 FRGs was developed to evaluate the risk of Ph-neg B-ALL patients. Conclusion Jointly our study proved the crucial role of ferroptosis in Ph-neg B-ALL and Sorafenib is likely to improve the survival of high-risk Ph-neg B-ALL patients. Keywords Ferroptosis Acute lymphoblastic leukemia Unsupervised clustering Sorafenib Immune Background 50 of B-ALL patients were negative in Philadelphia B cell acute lymphoblastic leukemia B-ALL diagnosis chromosome screening 2 and the prognosis of Phila- and treatment had

• Y khoa - Dược
• BMC Cancer
• Acute lymphoblastic leukemia
• Unsupervised clustering
• Philadelphia chromosome negative B cell
• Leukemia’s heterogeneity
• Cancer patient pathways
• Colorectal cancer
• Lung cancer
• Breast cancer
• Prostate cancer
• Ovarian cancer
• Cancer detection
• Ovarian cancer symptoms
• Ovarian cancer signs
• Ovarian cancer tests
• Cancer biomarkers
• Pediatric cancer
• Familial cancer predisposition
• Hereditary cancer syndrome
• Genetic cancer susceptibility
• Advanced cancer
• Biliary tract cancer
• Multimodal intervention
• Pancreatic cancer
• Physical activity
• Breast cancer screening
• Familial breast cancer
• Young breast cancer survivors
• High risk relatives
• Randomized trial
• Childhood cancer
• Childhood cancer survivor
• Thyroid cancer screening
• Secondary cancer
• Cancer screening
• Community awareness
• Cancer education
• Cervical cancer
• Prior cancer
• Cancer survivors
• Cancer registry
• Second cancer
• Surgical oncology
• Cancer imaging
• Radiation oncologists
• Medical oncologists
• Oesophagogastric cancer
• Liver cancer
• Hepatobiliary cancer
• Multidisciplinary rehabilitation
• EGFR mutation
• Family history of cancer
• Inherited susceptibility
• Cancer predisposition genes
• Lung cancer aetiology
• Cancer stem cells
• Oct4 overexpressing lung cancer
• Human lung cancer xenograft model
• Disease free survivals
• Cancer hallmarks
• Cancer genesis
• Defiant disease
• Mutational signature
• Cancer diagnosis
• Cancer genomics
• Molecular medicine
• Whole genome sequencing
• Cancer susceptibility gene
• Breast cancer prognosis
• Next generation sequencing
• Quality of care
• Quality indicators
• Shifting cancer care
• German cancer society
• Colorectal cancer screening
• Stomach cancer screening
• Lung cancer survivor
• Physician recommendation
• Total number of lymph nodes
• Lymph node ratio
• Left colon cancer
• Right colon cancer
• Overall survival
• Cumulative incidence
• Esophageal cancer
• Head and neck cancer
• Metachronous cancer
• Young onset
• Reproductive cancer
• Risk factor
• Early detection of cancer
• Gastric cancer incidence
• Population based specialized registry
• Gastric cancer survival
• Gastric cancer clinical characteristics
• Gastric cancer pathological characteristics
• Lung Cancer Screening
• Racial disparities
• Lung Cancer diagnosis
• Screening adherence
• Second primary colorectal cancer
• Standardized incidence ratio
• Left sided colon cancer
• Right sided colon cancer
• Quality of cancer care
• Population based study